Acurx Pharmaceuticals宣布欧洲药品管理局对伊贝扎波司他治疗儿童艰难梭菌感染的儿科研究计划给予积极意见_老虎社区_美港股上老虎

Acurx Pharmaceuticals宣布欧洲药品管理局对伊贝扎波司他治疗儿童艰难梭菌感染的儿科研究计划给予积极意见

美股速递2025-09-30

Acurx Pharmaceuticals宣布，欧洲药品管理局(EMA)对该公司伊贝扎波司他用于治疗儿童艰难梭菌感染的儿科研究计划给予了积极意见。这一积极意见为该药物在儿科患者中的进一步开发和应用奠定了重要基础。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1115056977?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-09-30 19:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115056977","market":"us","top_or_hot":-1,"title":"Acurx Pharmaceuticals宣布欧洲药品管理局对伊贝扎波司他治疗儿童艰难梭菌感染的儿科研究计划给予积极意见","media":"美股速递","content":"<p>Acurx Pharmaceuticals宣布，欧洲药品管理局(EMA)对该公司伊贝扎波司他用于治疗儿童艰难梭菌感染的儿科研究计划给予了积极意见。这一积极意见为该药物在儿科患者中的进一步开发和应用奠定了重要基础。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acurx Pharmaceuticals宣布欧洲药品管理局对伊贝扎波司他治疗儿童艰难梭菌感染的儿科研究计划给予积极意见</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcurx Pharmaceuticals宣布欧洲药品管理局对伊贝扎波司他治疗儿童艰难梭菌感染的儿科研究计划给予积极意见\n</h2>\n\n<h4 class=\"meta\">\n\n2025-09-30 19:33 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Acurx Pharmaceuticals宣布，欧洲药品管理局(EMA)对该公司伊贝扎波司他用于治疗儿童艰难梭菌感染的儿科研究计划给予了积极意见。这一积极意见为该药物在儿科患者中的进一步开发和应用奠定了重要基础。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1115056977","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115056977","pubTimestamp":1759231998,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Acurx Pharmaceuticals宣布，欧洲药品管理局(EMA)对该公司伊贝扎波司他用于治疗儿童艰难梭菌感染的儿科研究计划给予了积极意见。这一积极意见为该药物在儿科患者中的进一步开发和应用奠定了重要基础。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","BK4539":"次新股","ACXP":"Acurx Pharmaceuticals, LLC*","BK4563":"昨日强势股"},"translate_title":"Acurx Pharmaceuticals announces positive opinion from the European Medicines Agency on the pediatric study program of ibezabostat for the treatment of Clostridium difficile infection in children","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACXP":1},"content_text":"Acurx Pharmaceuticals宣布，欧洲药品管理局(EMA)对该公司伊贝扎波司他用于治疗儿童艰难梭菌感染的儿科研究计划给予了积极意见。这一积极意见为该药物在儿科患者中的进一步开发和应用奠定了重要基础。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}